Oligoprogression clinical trials

Explore recruiting oligoprogression clinical trials.

Recruiting oligoprogression studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Oligoprogression trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A phase II study to assess the efficacy of the anti-PD-L1 antibody atezolizumab (MPDL3280A) administered with stereotactic ablative radiotherapy (SABR) in patients with metastatic tumours (SABR-PDL1)

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Modified osimertinib dosing, with or without cobicistat as a pharmacokinetic booster, to improve cost-effectiveness of advanced Non-Small Cell Lung Cancer treatment - OSIBOOST 2

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

Oligoprogression trials by city

Oligoprogression in Toronto Oligoprogression in Vancouver Oligoprogression in Montreal Oligoprogression in Calgary Oligoprogression in Edmonton Oligoprogression in Ottawa Oligoprogression in Winnipeg Oligoprogression in Quebec City Oligoprogression in Hamilton Oligoprogression in Kitchener Oligoprogression in London Oligoprogression in Halifax Oligoprogression in New York Oligoprogression in Los Angeles Oligoprogression in Chicago Oligoprogression in Houston

Oligoprogression clinical trials

Recruiting oligoprogression studies right now

A Study on Using SFRT With Standard Treatment for Oligoprogressive NSCLC

Stereotactic Ablative Radiation Therapy for Abiraterone-Resistant, Oligoprogressive Metastatic Prostate Cancer

The Impact of Metastatic Directed Radiotherapy (MDRT) on Oligoprogressive Castration Resistant Prostate Cancer (CRPC)

Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy

Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Melanoma

Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer

Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)

COntinue the SaMe Systemic Therapy After Local Ablative Therapy for Oligo Progression in Metastatic Breast Cancer - the COSMO Study

Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic Cancers

Locally ablatiVe therApy in oLigO-pRogressive sOlid tUmorS (VALOROUS)

Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC

SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy

Also recruiting in Europe

A phase II study to assess the efficacy of the anti-PD-L1 antibody atezolizumab (MPDL3280A) administered with stereotactic ablative radiotherapy (SABR) in patients with metastatic tumours (SABR-PDL1)

Modified osimertinib dosing, with or without cobicistat as a pharmacokinetic booster, to improve cost-effectiveness of advanced Non-Small Cell Lung Cancer treatment - OSIBOOST 2

Oligoprogression trials by city

Other conditions